BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 2170823)

  • 1. Risks of estrogens and progestogens.
    L'Hermite M
    Maturitas; 1990 Sep; 12(3):215-46. PubMed ID: 2170823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use of oestrogens and progestogens.
    Lauritzen C
    Maturitas; 1990 Sep; 12(3):199-214. PubMed ID: 2215269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR; Ory H
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones.
    Adlercreutz H; Pulkkinen MO; Hämäläinen EK; Korpela JT
    J Steroid Biochem; 1984 Jan; 20(1):217-29. PubMed ID: 6231418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norgestimate: a clinical overview of a new progestin.
    Bringer J
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacology of newer progestogens.
    Kuhl H
    Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New knowledge in the physiology of hormonal contraceptives.
    Lobo RA; Stanczyk FZ
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of fertility with oral medication.
    Diddle AW; Watts GF; Gardner WH; Williamson PJ
    West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The menopause: benefits and risks of estrogen-progestogen replacement therapy.
    Gambrell RD
    Fertil Steril; 1982 Apr; 37(4):457-74. PubMed ID: 7040116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and mechanisms of cardiovascular events in users of oral contraceptives.
    Meade TW
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1646-52. PubMed ID: 3287935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Third generation progestagens].
    Belaisch J; Eliakim V
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):287-93. PubMed ID: 12318226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception.
    Contraception; 1980 May; 21(5):445-59. PubMed ID: 7428356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
    Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
    Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic impact of current estrogen-progestins and cardiovascular consequences].
    Gaspard U; Lambotte R
    Bull Mem Acad R Med Belg; 1991; 146(8-10):334-42; discussion 342-5. PubMed ID: 1815814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits and risks of oral contraceptive use.
    Williams RS
    Postgrad Med; 1992 Nov; 92(7):155-7, 161-2, 168-71. PubMed ID: 1437913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contraception for the transitional years of women older than 40 years of age.
    Upton GV; Corbin A
    Clin Obstet Gynecol; 1992 Dec; 35(4):855-64. PubMed ID: 1451368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum lipids and lipoproteins during treatment with oral contraceptives containing natural and synthetic oestrogens. A controlled double-blind investigation.
    Bostofte E; Hemmingsen L; Møller KJ; Serup J; Weber T
    Acta Endocrinol (Copenh); 1978 Apr; 87(4):855-64. PubMed ID: 347855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.